Möchten Sie immer auf dem neuesten Stand bleiben?

Kelly McKee to help shape Science 37’s future patient experience, driving growth through modernized trials, innovation, and cross-team collaboration.

Dublin, Jan. 26, 2026 (GLOBE NEWSWIRE) -- The "Central Nervous System Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031" has been added to ...

Data update from the ongoing Phase 1b/2 study of muzastotug + pembrolizumab in 3L+ MSS CRC patients remains on track for Q1 2026 Unaudited cash and cash equivalents of $74.5 million as of December...

L’amlitelimab de Sanofi confirme son potentiel dans la dermatite atopique Dans l'étude de phase 3 SHORE, l'amlitelimab en association avec des traitements topiques a atteint tous les critères...

Sanofi's amlitelimab confirms its potential in atopic dermatitis In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24...

Dublin, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The "Pharmaceutical Spray Drying - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)" has been added to ...

Ottawa, Jan. 22, 2026 (GLOBE NEWSWIRE) -- The global clinical trials market size is calculated at USD 93.15 billion in 2025, grew to USD 99.21 billion in 2026, and is projected to reach around USD...

COMMUNIQUÉ DE PRESSE AB SCIENCE OBTIENT UN BREVET JAPONAIS POUR L'UTILISATION DU MASITINIB DANS LE TRAITEMENT DES FORMES PROGRESSIVES DE LA SCLÉROSE EN PLAQUES (SEP) JUSQU'EN 2041 IL S'AGIT DU...

PRESS RELEASE AB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL 2041 THIS IS THE FIRST COUNTRY DELIVERING THE MS PATENT ...

BrightInsight adds three health industry veterans to its Executive Leadership Team to scale operations and maintain the company's growth trajectory.